OverviewSuggest Edit

EpiVax uses "immunoinformatics" computer modeling, gene sequencing and molecular immunology to develop new vaccines and to improve the immunogenicity profiles of new drugs. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. EpiVax won the prestigious AAPS Innovation award for its Tregitope technology. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity" meetings. By 2006, EpiVax had developed a reputation as “thought leaders” in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to <20 for its competitors). EpiVax’ 22 employees are “an incredibly creative group,” says De Groot, the company’s CEO and CSO. “We try to foster a balance between customer focus, Yankee frugality, and intellectual curiosity,” she says. “The critical components of our company’s innovations process are free thought, unencumbered imagination and an ability to connect the dots.” The EpiVax team also prides itself on delivering on promises. “We maintain a close relationship with our clients,” De Groot says. We aim to treat our clients with respect and provide capable, intelligent solutions for their needs.”
HQProvidence, RI, US
Employee Ratings3.9

Latest Updates

Employees (est.) (Jun 2021)38(+3%)
Cybersecurity ratingBMore

Key People/Management at EpiVax

William Martin

William Martin

Clifford Grimm

Clifford Grimm

Leonard Moise

Leonard Moise

Scientific Director, Vaccine Research
Frances Terry

Frances Terry

Director of Analysis
Anne S. De Groot

Anne S. De Groot

Founder, CEO & CSO
Show more

EpiVax Office Locations

EpiVax has an office in Providence
Providence, RI, US (HQ)
188 Valley St #424
Show all (1)

EpiVax Financials and Metrics

Summary Metrics

Founding Date


EpiVax total Funding

$3.2 m

EpiVax latest funding size

$55 k

Time since last funding

9 years ago

EpiVax investors

EpiVax's latest funding round in November 2012 was reported to be $55 k. In total, EpiVax has raised $3.2 m
Show all financial metrics

EpiVax Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

EpiVax Online and Social Media Presence

Embed Graph

EpiVax News and Updates

FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities

PROVIDENCE, R.I., Oct. 22, 2020 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food and Drug...

Intravacc and EpiVax Team up in Development of COVID-19 Emerging Vaccine

BILTHOVEN, Netherlands and PROVIDENCE, Rhode Island, June 2, 2020 /PRNewswire/ -- Intravacc, one of the world's leading translational research and development vaccine institutes, with an extensive track record in developing viral and bacterial vaccines, and EpiVax, a biotechnology company...

EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries

PROVIDENCE, R.I., April 7, 2020 /PRNewswire/ -- EpiVax, Inc., is using advanced computational tools to accelerate a COVID-19 vaccine candidate (EPV-CoV19) for healthcare workers (HCW) into clinical trials in 6 months. Today, EpiVax announces its partnership with GAIA Vaccine Foundation...

EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports

PROVIDENCE, R.I., Nov. 6, 2019 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in...

EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

NEW YORK, March 25, 2019 /PRNewswire/ -- EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for an oral presentation, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, taking place on...

EpiVax Oncology Appoints Dominique Bridon as Chief Technology Officer and Dan Adams to the Board of Directors

NEW YORK and PROVIDENCE, R.I., Oct. 22, 2018 /PRNewswire/ -- EpiVax Oncology, Inc., a precision cancer immunotherapy company, is pleased to announce the appointment of Dominique Bridon as Chief Technology Officer and the appointment of Dan Adams to the Board of Directors, both effective...
Show more

EpiVax Blogs

Host Cell Proteins in COVID Vaccines? and …. Fearless Science World Tour!

The Curious Case of HCP-driven Immunogenicity The FDA briefly “paused” the Johnson &amp; Johnson adenovirus-based COVID-19 vaccine in April, and the AstraZeneca vaccine (also adenovirus-based) was in the news as early as March. Both of these pauses were to investigate rare but serious cases of blood…

Meet the 6 newest EpiVax team members!

The post Meet the 6 newest EpiVax team members! appeared first on EpiVax, Inc. - Informatics and Immunology.

AAPS NBC Tech Challenge Talk: Engineering Better Biologics: Does Nature Know Best?

The post AAPS NBC Tech Challenge Talk: Engineering Better Biologics: Does Nature Know Best? appeared first on EpiVax, Inc. - Informatics and Immunology.

EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies peptide epitopes associated with T cell…

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics’ Ancer Platform

PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method of survival analysis for cancer patie…

Vax Gives Back: Winter 2021 Activities

The post Vax Gives Back: Winter 2021 Activities appeared first on EpiVax, Inc. - Informatics and Immunology.
Show more

EpiVax Frequently Asked Questions

  • When was EpiVax founded?

    EpiVax was founded in 1998.

  • Who are EpiVax key executives?

    EpiVax's key executives are William Martin, Clifford Grimm and Leonard Moise.

  • How many employees does EpiVax have?

    EpiVax has 38 employees.

  • Who are EpiVax competitors?

    Competitors of EpiVax include IDEX Health & Science, The Biomedical Engineering Society and Althea.

  • Where is EpiVax headquarters?

    EpiVax headquarters is located at 188 Valley St #424, Providence.

  • Where are EpiVax offices?

    EpiVax has an office in Providence.

  • How many offices does EpiVax have?

    EpiVax has 1 office.